1	Deep Learning-Based Multimodal Clustering Model for Endotyping and Post-Arthropla				
2	Response Classification using Knee Osteoarthritis Subject-Matched Multi-Omic Data				
3					
4	Jason S. Rockel ^{1,2*} , Divya Sharma ^{1,3,4*} , Osvaldo Espin-Garcia ^{1,2,3,5*} , Katrina Hueniken ^{1,2,4*} , Amit				
5	Sandhu ^{1,2*} , Chiara Pastrello ^{1,2*} , Kala Sundararajan ^{1,2} , Pratibha Potla ^{1,2} , Noah Fine ^{1,2} , Starlee S.				
6	Lively ^{1,2} , Kimberly Perry ^{1,2} , Nizar N. Mohamed ^{1,2,6} , Khalid Syed ^{1,2,6} , Igor Jurisica ^{1,2,#} , Anthony				
7	V. Perruccio ^{1,2,6,8,#} , Y. Raja Rampersaud ^{1,2,6,#} , Rajiv Gandhi ^{1,2,6,7,#} and Mohit Kapoor ^{1,2,6,7,#,+}				
8					
9	1. Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute,				
10	University Health Network, Toronto, Ontario, Canada				
11	2. Krembil Research Institute, University Health Network, Toronto, Ontario, Canada				
12	3. Department of Biostatistics, Dalla Lana School of Public Health, University of Toronto,				
13	Toronto, Ontario, Canada				
14	4. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada				
15	5. Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada				
16	6. Department of Surgery, University of Toronto, Toronto, Ontario, Canada				
17	7. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto,				
18	Ontario, Canada				
19	8. Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health,				
20	University of Toronto, Toronto, Ontario, Canada				
21					
22	* equal first author contribution				
23	# equal senior author contribution				
24					
25	+ Correspondence: mkapoor@uhnresearch.ca; Schroeder Arthritis Institute, 60 Leonard Avenue,				
26	5 th floor Krembil Discovery Tower, Toronto, Ontario, Canada.				

27 Abstract

28

Background: Primary knee osteoarthritis (KOA) is a heterogeneous disease with clinical and molecular contributors. Biofluids contain microRNAs and metabolites that can be measured by omic technologies. Deep learning captures complex non-linear associations within multimodal data but, to date, has not been used for multi-omic-based endotyping of KOA patients. We developed a novel multimodal deep learning framework for clustering of multi-omic data from three subject-matched biofluids to identify distinct KOA endotypes and classify one-year posttotal knee arthroplasty (TKA) pain/function responses.

36

37 Materials and Methods: In 414 KOA patients, subject-matched plasma, synovial fluid and urine 38 were analyzed by microRNA sequencing or metabolomics. Integrating 4 high-dimensional 39 datasets comprising metabolites from plasma (n=151 features), along with microRNAs from 40 plasma (n=421), synovial fluid (n=930), or urine (n=1225), a multimodal deep learning variational 41 autoencoder architecture with K-means clustering was employed. Features influencing cluster 42 assignment were identified and pathway analyses conducted. An integrative machine learning 43 framework combining 4 molecular domains and a clinical domain was then used to classify 44 WOMAC pain/function responses post-TKA within each cluster.

45

46 Findings: Multimodal deep learning-based clustering of subjects across 4 domains yielded 3 47 distinct patient clusters. Feature signatures comprising microRNAs and metabolites across 48 biofluids included 30, 16, and 24 features associated with Clusters 1-3, respectively. Pathway 49 analyses revealed distinct pathways associated with each cluster. Integration of 4 multi-omic 50 domains along with clinical data improved response classification performance, with Cluster 3 51 achieving AUC=0.879 for subject pain response classification and Cluster 2 reaching AUC=0.80852 for subject function response, surpassing individual domain classifications by 12% and 15% 53 respectively.

54

55 Interpretation: We have developed a deep learning-based multimodal clustering model capable 56 of integrating complex multi-fluid, multi-omic data to assist in KOA patient endotyping and test 57 outcome response to TKA surgery.

- 58 Funding: Canada Research Chairs Program, Tony and Shari Fell Chair, Campaign to Cure
- 59 Arthritis, University Health Network Foundation.
- 60
- 61 Keywords: Osteoarthritis; Variational Autoencoder; Machine-Learning; Endotyping; Multi-
- 62 omics; Response Classification

63

65 Introduction

66

67 Osteoarthritis (OA) is a degenerative, painful and disabling joint disease affecting over 500 million people worldwide,¹ with the knee most commonly afflicted². Primary knee (K)OA patients are 68 69 heterogeneous³. Risk factors of KOA include age, sex, and obesity status.² Mental health and 70 persistent pain status have also associated with KOA clinical phenotypes.^{4,5} Total joint 71 arthroplasty (TKA) is the only available therapy for KOA patients who no longer respond to 72 conservative management; however, up to 34% of KOA patients with TKA fail to achieve 73 clinically-relevant pain reduction.⁶ Identifying those at high risk of non-response is of significant 74 interest. It is possible that KOA heterogeneity captured by biological features may improve our 75 ability to classify patient responses to TKA.

Biofluid microRNAs (miRNAs) and metabolites can provide highly descriptive, individualized categorizations of patients beyond clinical measures. MiRNAs epigenetically modify target RNA expression. Biofluid metabolomes represents snapshots of the metabolic activity contributed by associated cells and tissues. Advanced omic technologies can measure miRNAs (miRNomics) and metabolites (metabolomics), primarily by next generation sequencing (NGS) and liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS), respectively.^{7,8}

82 In a case-control study using the UK Biobank cohort, 14 distinct OA risk phenotypes were 83 identified by multi-modal machine learning (ML) using clinical factors alone.⁹ The inclusion of 84 individual proteomics, genomics or metabolomics data showed no prediction improvement of case-control status over clinical factor modeling alone.⁹ In contrast, studies using individual 85 86 biofluids have identified endotypes of OA patients. Three endotypes of OA patients (low tissue 87 turnover, structural damage and systemic inflammation) were identified from a panel of 16 serum 88 and urine proteins/peptides using unsupervised ML.¹⁰ Plasma metabolomics alone uncovered multiple endotypes of KOA patients,^{11,12} with some endotype-related metabolite ratios able to 89 90 differentiate specific endotypes of KOA subjects from control participants.¹¹ KOA patient biofluid 91 miRNA signatures were also able to differentiate between slow and fast progressors,¹³ early and late KOA,^{14,15} and patients requiring TKA or not.¹⁶ Thus, endotype data from biofluids is 92 93 important for understanding KOA heterogeneity, and, consequently, may be associated with 94 patient outcomes. To our knowledge, KOA endotypes have yet to be evaluated across multiple 95 biofluids using multi-omic technologies in an integrated approach.⁸

96 Our experience to date suggests that multi-biofluid, mult-omic endotyping requires more complex 97 modeling systems. Deep learning aids in extracting complex patterns from data. However, 98 integrating multimodal data from multiple sources presents challenges due to the diversity within 99 and across data types. Variational Autoencoders (VAEs) address this challenge by embedding 100 diverse data domains into reduced latent dimensions, facilitating improved data clustering.¹⁷⁻¹⁹ 101 Despite the potential of VAEs, there is a lack of unified frameworks for leveraging these methods 102 to identify clusters from multimodal data and to classify clinical responses by integrating diverse 103 data domains. Additionally, VAEs have not been applied to investigate OA endotypes. 104 In this study, we developed a novel multimodal deep learning framework employing VAEs for

in this study, we developed a novel mathinodal deep rearing numework employing vites for integrative clustering using 4 high-dimensional domains of subject-matched multi-omic data from synovial fluid, urine and plasma and tested its ability to determine distinct clusters (endotypes) of a sample of KOA patients. Leveraging these endotypes, we further developed an integrative ML framework and tested the potential of this methodology to assess pain and function responses to TKA surgery.

110

111 Methods

112

113 Study Sample

114 A sample of 414 patients with primary KOA who underwent TKA within the Longitudinal 115 Evaluation in the Arthritis Program-OA cohort (University Health Network, Toronto, ON, Canada), as previously described,²⁰ and who had synovial fluid (collected intra-operatively), 116 117 plasma and urine (collected up to 3 months prior to surgery) available, were selected for analysis. 118 Subjects completed self-reported, multidimensional questionnaires from which baseline Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain and function,²¹ Hospital 119 Anxiety and Depression Scale (HADS)²² and painDETECT²³ at baseline (completed within the 3-120 121 months preceding surgery), and WOMAC pain and function 1-year post-TKA, were calculated. 122 Improvement in WOMAC pain and function from baseline to 1 year post-TKA was calculated and 123 individuals were categorized as responders (>33% improvement) or non-responders (\leq 33% 124 improvement). HADS depression and anxiety scores were each categorized as normal (score 0-7), borderline case (score 8-11), and definite case (score 11-21)²². PainDETECT neuropathic-like pain 125 126 scores were used to classify patients pain as likely nociceptive (score 0-12), unclear (score 13-18),

or likely neuropathic (score 19-38).²³ Baseline age, sex, and weight and height [from which body
mass index (BMI; kg/m²) was calculated] were also collected. Biofluids and patient data were
collected with written informed consent from each patient and Research Ethics Board approval of
the University Health Network, Toronto, ON (REB# 07-0383-BE; 14-7592-AE).

131

132 MiRNA sequencing (miRNomics) and metabolomics

133 MiRNA extraction was performed using 200 µL plasma (N=414), 100 µL synovial fluid (N=414), and 1 ml urine (N=414). cDNA libraries were prepared using a protocol we previously reported.¹⁵ 134 135 NGS was conducted at the Schroeder Arthritis Institute (Toronto) sequencing facility using the 136 Illumina NextSeq550 platform. Alignment, processing and quality assessment was performed 137 using a previously reported pipeline.²⁴ Targeted metabolomics was used to profile 188 metabolites 138 (Biocrates AbsoluteIDQ p180 kit, Biocrates Life Sciences AG, Austria) in N=414 plasma samples 139 at The Metabolomics Innovation Centre (Calgary, Alberta) by LC-MS/MS, as previously described.¹² Metabolite quantification and batch correction was conducted using the Absolute 140 141 IDO-coupled MetIDO software (Biocrates). MiRNA count data and metabolite concentrations were normalized using sum normalization, log-transformation, and Pareto scaling.²⁵ To stabilize 142 143 variance estimates within differential expression analysis, empirical Bayes moderation techniques 144 were applied.

145

146 OmicVAE: integrative variational autoencoder architecture for multimodal clustering

We generated a novel variational autoencoder (VAE) architecture named '*omicVAE*' designed to cluster multimodal multi-omic data (Figure 1). *OmicVAE* consists of a single encoder network followed by 4 individual decoder networks, to perform integrative clustering combining 4 modalities: metabolomics, miRNA plasma, miRNA synovial fluid, and miRNA urine.

The encoder network inputs concatenated multimodal multi-omic data and maps it to a shared latent space representation using multiple fully connected neural network (FNN) layers with sigmoid activation. The encoder network's output layers parameterize the mean and variance of a Gaussian distribution representing the shared latent space. Each decoder network reconstructs its respective domain's input data from samples drawn from this latent space, using multiple fully connected neural network (FNN) layers. During training, variational inference optimizes the VAE's parameters. The objective function L_{total} includes the reconstruction loss (L_{rec}) and the

- 158 Kullback-Leibler (KL) divergence (L_{KL}) between the learned latent distribution and a predefined
- 159 prior (eqs. 1-3). Minimizing KL divergence regularizes the latent space, preventing overfitting and
- 160 ensuring it remains structured and interpretable. The reconstruction loss measures the discrepancy
- 161 between the input data and its reconstruction by the VAE decoder for each modality.

162
$$L_{rec} = \frac{1}{N_{metabolites}} \sum_{i=1}^{N} ||X_{metabolites(i)} - Decoder_{metabolites(i)}(z)||^{2} +$$

163
$$\frac{1}{N_{miRNA_{plasma}}} \sum_{i=1}^{N} ||X_{miRNA_{plasma}(i)} - Decoder_{miRNA_{plasma}(i)}(z)||^{2} +$$

164
$$\frac{1}{N_{miRNA_{synovial}}} \sum_{i=1}^{N} ||X_{miRNA_{synovial}(i)} - Decoder_{miRNA_{synovial}(i)}(z)||^{2} +$$

165
$$\frac{1}{N_{miRNA_{urine}}} \sum_{i=1}^{N} ||X_{miRNA_{urine}(i)} - Decoder_{miRNA_{urine}(i)}(z)||^2$$
(1)

166

167
$$L_{KL} = -\frac{1}{2}((1 + \log(\sigma_{metabolites}^2) - \mu_{metabolites}^2 - \sigma_{metabolites}^2) +$$

168
$$(1 + \log\left(\sigma_{miRNA_{plasma}}^2\right) - \mu_{miRNA_{plasma}}^2 - \sigma_{miRNA_{plasma}}^2) +$$

169
$$(1 + \log\left(\sigma_{miRNA_{synovial}}^{2}\right) - \mu_{miRNA_{synovial}}^{2} - \sigma_{miRNA_{synovial}}^{2}) +$$

170
$$(1 + log(\sigma_{miRNA_{urine}}^2) - \mu_{miRNA_{urine}}^2 - \sigma_{miRNA_{urine}}^2))$$
(2)

171

$$172 L_{total} = L_{rec} + L_{KL} (3)$$

173 where i represents the samples in each modality, X is the input data, Decoder(z) is the

174 reconstructed data, and μ and σ denote the mean and variance of the Gaussian distribution in the 175 latent space. Once omicVAE is trained, K-means clustering on the learned latent space is used to 176 identify distinct subpopulations within the multimodal multi-omic data.

177

178 *Multi-omic signature identification within each cluster*

We employed a comprehensive approach to identify signature features (miRNAs and/or metabolites within three biofluids) influencing cluster assignment within each domain. We concurrently conducted standardized mean differences (SMD) analysis and differential expression (DE) analysis for pairwise cluster comparisons (one cluster vs others), using Benjamini-Hochberg (BH) adjusted p-values (q < 0.05) to identify significant features. By integrating these analyses,

184 we identified features with both large SMDs and significant DE, capturing robust signature185 features distinguishing clusters.

186

187 Endotype pathway analysis

188 MiRNAs gene targets per cluster were identified using the top 1% of targets per miRNA using 189 mirDIP v. 5.2 (https://ophid.utoronto.ca/mirDIP)²⁶ We performed pathway enrichment analysis 190 for sets of gene targets in each cluster using pathDIP 5 (https://ophid.utoronto.ca/pathDIP).²⁷ Diseases, drugs and vitamins, and genetic information processing pathway types were excluded 191 192 from enrichment analysis. Only pathways with q-value (BH adjusted) <0.01 were considered. 193 Metabolite pathway enrichment analysis was not possible, so we identified pathways that included 194 metabolites specific for each cluster for further analyses. Selected pathways specific for each 195 cluster were visualized using NAViGaTOR 3.0.19 196 (https://navigator.ophid.utoronto.ca/navigatorwp).²⁸ Mapping of pathways to consolidated 197 categories in pathDIP was used to calculate the number of pathways per category. ggradar2 1.1.0 198 in R 4.3.0 was subsequently used to plot their distribution per cluster, scaling category pathway 199 counts from 0% to 100%.

200

201 Integrative machine learning framework for classifying response

202 We developed a comprehensive two-step ML framework (Figure 4a) to integrate plasma 203 metabolites, miRNA plasma, miRNA synovial fluid, and miRNA urine domain, along with clinical 204 domain (consisting of age, sex, BMI, depression and anxiety categories, and neuropathic pain 205 category), to classify 1-year pain and function responses (i.e. responders vs non-responders). In 206 the first step, we trained separate unimodal ML models for each domain to extract features 207 classifying 1-year response. We utilized the MICE library in R for imputing missing clinical data 208 (missingness <8%). We explored various ML algorithms, including logistic regression, lasso 209 regression, ridge regression, support vector machines and random forests, selecting models based 210 on 10-fold cross-validation performance.

211

In the second step, we integrated features from all domains using a naïve-Bayes meta-classifier, trained with classifiers from the unimodal models. Cross-validation was used for performance estimation and hyperparameter tuning. The final classification was generated by the meta-

215 classifier based on integrated features. Model evaluation involved assessing the overall framework

216 performance using area under the receiver operating characteristic curve (AUC) and analyzing

217 feature importance with mean Gini impurity metrics.

218

219 Role of the Funding Sources

Funders had no role in study design, data collection and analysis, decision to publish, ormanuscript writing.

222

223 Findings

224

225 Endotype and signature identification using omicVAE and K-means clustering

We first sought to identify endotypes from our sample of 414 KOA patients. The patient sample was 57% female, with a mean age (\pm sd) of 65·7 \pm 8·7 years, and BMI (\pm sd) of 31 \pm 7·1 kg/m². The majority of subjects had anxiety or depression symptom scores in the normal range and the majority had painDETECT scores indicating likely nociceptive pain. Mean baseline WOMAC pain score for the sample was 10·1 \pm 3·5 points on a 20 total point scale, and baseline WOMAC function score was 34·9 \pm 11·9 points on a 68 total point scale (Supplementary Table 1).

232 After metabolomics and miRNomics analyses of plasma, synovial fluid and urine, our analytical 233 dataset consisted of 2727 molecular features from 4 domains: 151 plasma metabolites, 421 plasma 234 miRNAs, 930 synovial fluid miRNAs, and 1225 urine miRNAs. We then developed omicVAE 235 with K-means clustering (Figure 1), which uncovered three clusters of patients using the 4 domains 236 (Figure 2a). Distribution of most baseline clinical, demographic and anthropometric measures 237 were similar across clusters, except cluster 3 that had a higher proportion of subjects with 238 depression scores in the normal range, and cluster 1 that had a higher proportion of subjects with 239 likely neuropathic pain (Table 1).

Significant features associated with each cluster were identified by the intersection of differential
expression and standardized mean difference analyses. Distinct signatures consisting of 30, 16 and
24 features for clusters 1-3, respectively, were identified (Figure 2b and Supplementary Table 2).
Notably, each signature contained features from all 4 domains. In Cluster 1, the highest mean
value difference was observed for synovial fluid hsa-miR-2053. In Cluster 2, synovial fluid hsa-

miR-496 exhibited the highest mean value. In Cluster 3, plasma hsa-miR-570-3p had the highest
mean value. Thus, each cluster represents a group of subjects with a distinct endotype.

247

248 Endotype feature signatures are enriched for unique pathways

249 We next sought to determine if cluster endotype signatures were associated with unique 250 physiological pathways. We first identified putative miRNA-gene targets using mirDIP,²⁶ 251 identifying 3257, 2211, and 2319 individual genes targeted by the miRNAs in each of the endotype 252 signatures associated with clusters 1-3, respectively. Using these gene set lists, we performed 253 enrichment analysis using pathDIP (Supplementary Table 3-5).²⁷ For metabolites in each endotype 254 signature, pathway annotations were also identified using pathDIP (Supplementary Table 6-8). All 255 pathways were also annotated with categories in pathDIP. For each endotype, individual miRNA-256 gene targets and metabolites were linked to some common as well as unique pathways. The top 257 unique enriched and annotated pathways linked to miRNA-targeted genes or metabolites, 258 respectively, for each endotype are displayed in a network showing individual pathways and 259 categories (Figure 3a, Supplementary Figures 1-3).

260 We next used pathway categories to evaluate physiologically-relevant mechanisms linked to each 261 endotype. Each enriched miRNA-derived pathway or annotated metabolite pathway was counted 262 based on its category annotation in pathDIP, scaled and visualized using radar plots (Figure 3b). 263 The cluster 1 endotype signature was most linked to pathway categories associated with 264 development and regeneration, membrane transport, metabolism of various molecules, and the 265 nervous system. The cluster 2 endotype signature was most linked to aging, and cellular 266 community categories. Finally, the cluster 3 endotype signature was most linked to transport and 267 catabolism, signal transduction, sensory system, endocrine system, excretory system, immune 268 system, catabolism, and lipid metabolism categories. Overall, these analyses suggested that 269 features associated with each endotype were uniquely associated with distinct physiological 270 pathways.

271

272 Evaluation of classification performance for WOMAC pain and function responses

To determine the classification performance of our clusters for identifying post-TKA WOMAC
pain and function response status, we used an integrative ML framework using five domains—
plasma metabolites, plasma miRNAs, synovial fluid miRNAs, urine miRNAs, and clinical data

276 (age, sex, BMI, anxiety and depression categories, and neuropathic pain category; Figure 4a). 277 Subject clusters had similar mean pain and function scores 1 year post-TKA, change in scores 278 from baseline to 1 year, as well as pain and function response rates (Table 1). We first conducted 279 differential expression analysis in each cluster, identifying metabolites with a fold-change of 1.1280 and miRNAs within each biofluid with a fold change of 1.5 between responders and non-281 responders. Subsequently, we employed 10-fold cross-validation to estimate the AUC. Of the ML 282 approaches compared, random forests consistently outperformed others in each individual domain 283 (Supplementary Table 9) and was used for the unimodal ML models.

284 After differential analysis-based feature selection, cluster 1-3 retained 250, 87, and 49 features, 285 respectively for the ML analysis to classify pain response (Supplementary Table 10). Initially, 286 unimodal models were applied to each domain. Within cluster 1, miRNA plasma demonstrated 287 the highest unimodal performance with an AUC of 0.735. However, the integrative performance, 288 combining all 4 domains in the meta-classifier, notably improved AUC to 0.841 (highlighted in 289 red in the ROC plot). For cluster 2, the clinical domain had the highest unimodal AUC of 0.740, 290 while the integrative AUC was 0.816. Cluster 3 achieved the highest integrative AUC of 0.879, 291 with miRNA urine showing the highest unimodal AUC of 0.786 (Figure 4b).

Based on differential analysis-based feature selection to classify function response, clusters 1-3
retained 63, 46, and 46 features, respectively, for the ML analysis (Supplementary Table 11).
Across clusters 1-3, the clinical data domain consistently exhibited the best performance among
unimodal domains, with AUCs of 0.702, 0.791, and 0.722, respectively. In terms of integrative
performance, clusters 1-3 achieved AUCs of 0.786, 0.808, 0.738 (Figure 4c), respectively.

297

298 Identifying key response classification features in our multimodal machine learning framework

299 To enhance the interpretability of our model we identified the most important features (molecular 300 and clinical) contributing to response classification in each cluster. The top 20 features 301 contributing to WOMAC pain or function response classification are shown in Supplementary 302 Figures 4 & 5, respectively. Each top 20 list consisted of features from all 4 molecular domains, 303 with a notable absence of clinical features; however, all molecular and clinical features inherently 304 played a role in response classification (Supplementary Tables 12&13). Interestingly, only 3 305 miRNAs overlapped in the top 20 important features for WOMAC pain response between clusters 306 2 & 3, namely synovial fluid hsa-miR-1265 and hsa-mir-642a-3p, plasma hsa-3942-5p. In

307 addition, only the metabolite glutamine overlapped in the top 20 important feature lists of clusters 308 2 & 3 for WOMAC function response. Thus, using our integrative approach, the vast majority of 309 the most important features for response classification were unique for each cluster and were 310 primarily driven by molecular entities. Overall, these findings highlight the diverse molecular 311 features associated with outcome classification in each cluster, emphasizing the importance of 312 integrating multiple domains for classification modeling of WOMAC pain and function responses 313 post-TKA.

314

315 Interpretation

316

317 Demographic, anthropometric and clinical characteristics of OA patients are heterogeneous, influencing outcomes to therapy, including TKA.^{3,29} Heterogeneity has also been identified 318 319 through biofluid data, however, most studies to date have used single biofluids with single molecular type measures to identify endotypes within OA cohorts.^{10,11} We developed a novel 320 321 multimodal deep learning algorithm, *omicVAE*, to cluster a sample of 414 KOA subjects who 322 underwent TKA using preoperative miRNA and metabolite feature sets, identified by miRNomics 323 and targeted metabolomics, from plasma, synovial fluid and urine, and uncovered three unique 324 cluster endotypes. To our knowledge, our study is the first to use patient-matched multi-fluid, 325 multi-omic approach to KOA patient endotyping. Not only did we uncover three unique multi-326 omic-based cluster endotypes, each was linked to unique biologically-relevant pathways. Despite 327 a similar clinical phenotype, the cluster 1 endotype was primarily linked to metabolic processes 328 and nervous system pathways, the cluster 2 endotype was primarily associated with aging 329 pathways, and the cluster 3 endotype was primarily linked to immune, endocrine, and lipid 330 metabolism pathways. Overall, the cluster endotypes uncovered are likely to contribute to, or be 331 the result of, distinct mechanisms associated with KOA patients. Finally, using this novel approach 332 to cluster endotyping, combined with integrative multimodal ML, we enhanced classification of 333 patient-reported pain and function responses beyond that achieved using clinical measures alone. 334 Surprisingly, it was the molecular entities that primarily drove classification of pain and function 335 responses using our integrative modeling. Overall, our unique methodological approach reduced 336 OA patient heterogeneity by defining patient clusters that had intra-cluster molecular differences 337 that enhanced classifing pain and function responses to TKA. As endotypes are further refined and

338 molecular entities best associated with classification are further characterized, it will be important 339 to understand how these response-based signatures may relate to physiological responses post-340 surgery.

341 The strength of our methodology lies in developing integrative deep learning and ML techniques 342 for efficient multi-omic endotyping and response classification in KOA patients. VAEs offer 343 advantages to integrating multiple domains for clustering compared to traditional approaches by 344 effectively capturing the underlying structure of heterogeneous data through a joint latent 345 representation. While traditional approaches such as dimensionality reduction or sequential 346 clustering may provide insights, they often suffer from limitations such as difficulty in capturing 347 non-linear relationships, and inadequate integration of domain-specific characteristics. Unlike 348 standard VAEs,¹⁹ we employed 4 separate decoders, enabling domain-specific reconstruction 349 facilitating robust subject clustering, accounting for the inherent uncertainty in the latent space via 350 the VAE's probabilistic nature. Overall, VAEs effectively leverage complementary information 351 from multiple modalities for a more comprehensive characterization of KOA patient endotypes.

352 The integration of multiple data domains through our comprehensive two-step ML framework 353 represents a significant advancement in response modeling for KOA outcomes by combining 354 complementary information inherent in metabolomics, miRNA, and clinical data domains. 355 Utilization of unimodal ML models in the first step allowed for extraction of domain-specific 356 features that could classify 1-year TKA pain and function responses, while subsequent integration 357 of these features using a naïve-Bayes meta-classifier enhanced classification accuracy. Naïve-358 Bayes classifiers emulate aspects of clinical decision-making by probabilistically combining evidence from multiple sources to make classifications.³⁰ Importantly, our novel framework 359 360 demonstrated improvements in classification performance compared to unimodal domain-specific 361 models, underscoring the utility of an integrative approach.

Although we included three biofluids to integrate miRNA or metabolite features to identify endotypes among KOA patients, additional endotypes may exist. Incorporating additional omic technologies (e.g. proteomics, genomics, methylomics) in the presented framework, as well as comprehensively evaluating omic measures across all biofluids may further refine endotypes, or uncover additional endotypes to further improve our understanding of KOA and ability to more accurately classify responses to interventions. Future studies should also focus on easily obtained patient biofluids, such as urine and blood, to determine if the presented approach can show similar

369 endotyping capability and response classification accuracy. In response classification modelling, 370 we only evaluated a subset of clinical and demographic variables associated with KOA and patient 371 outcomes to TKA, but incorporation of additional patient-related clinical and sociodemographic 372 variables (e.g. comorbidities, medication use, race etc.), alongside endotype data, may also help 373 improve modeling accuracy. Although we extensively validated our integrative ML unimodal 374 models using a 10-time, 10-fold cross-validation, a lack of external validation remains. For 375 external validation to be accomplished, better patient clinical and sociodemographic annotations, omic data and biosample sharing practices, and harmonization are needed.^{7,8} Lastly, similar 376 377 evaluations in additional patient cohorts, such as those with early-KOA and other afflicted joints, 378 or evaluating other response measures, would also be of interest moving forward.

Overall, using our novel modelling framework, we were able to unravel some heterogeneity of a sample of late-stage surgical KOA patients and evaluate post-TKA response classification. We anticipate this methodological approach will aid in understanding underlying molecular contributors and pathways to clusters of OA patients, and define molecular signatures contributing to intervention response. With additional studies, our methodological approach could ultimately help in shared patient-clinician decision making with regard to proceeding with selected therapies, including TKA for primary KOA.

386

387 Contributors

388 JSR, DS, OEG, KH, AS, YRR, AVP, RG and MK conceptualized the study. NNM, K. Syed, AVP, 389 YRR, RG and MK supervised patient data and biofluid collection. KP managed biofluid and 390 patient data storage. JSR, DS, OEG, KH, AS, CP, IJ, K. Sundararajan, YRR, AVP, RG and MK 391 processed and curated the data. JSR, DS, OEG, KH, AS, CP, PP, NF, IJ and MK created the 392 methodology and validated the data. DS developed the deep learning and machine learning 393 algorithms. DS, OEG, and KH performed statistical analyses. JSR, DS, CP, IJ and MK created 394 figures and tables. JSR, DS, KH, AS, CP and MK wrote the manuscript. MK supervised and 395 acquired funding for multi-omic analysis. All authors had full access to the study data, were 396 involved in manuscript editing, and were responsible for the decision to submit for publication.

397

398 Data Sharing

399 De-identified subject primary microRNA sequencing datasets are available on the Gene 400 Expression Omnibus under accession number GSE222979. Software code and the dataset of 401 processed miRNA counts, metabolite concentrations and demographic, anthropometric and 402 clinical questionnaire responses used in this study is available at 403 https://github.com/divya031090/DeepLearning KOA.

404

405 **Declaration of Interests**

- 406 We declare no competing interests.
- 407

408 Acknowledgments

409 Funding for this project was provided by the Canada Research Chairs Program (MK), Tony and 410 Shari Fell Platinum Chair in Arthritis Research (MK), Campaign to Cure Arthritis, University 411 Health Network Foundation. AVP is supported by the Arthritis Society Canada STAR Award-20-412 0000000012 and YRR is supported by J. Bernard Gosevitz Chair in Arthritis Research at 413 University Health Network. Computational analysis was supported in part by funding from 414 Natural Sciences and Engineering Research Council of Canada (NSERC RGPIN-2024-04314), 415 Canada Foundation for Innovation (CFI #225404, #30865), and Ontario Research Funds (RDI 416 #34876, RE010-020). The funders had no role in study design, data collection and analysis, 417 decision to publish, or preparation of the manuscript. Authors would like to thank the clinical 418 research team within the Division of Orthopedics and members of the Buchan Arthritis Center at 419 the Schroeder Arthritis Institute for their assistance in study recruitment. We also thank Dr. Max 420 Kotlyar for his assistance during initial discussions related to the study.

422 <u>References</u>

Long H, Liu Q, Yin H, et al. Prevalence Trends of Site-Specific Osteoarthritis From 1990
to 2019: Findings From the Global Burden of Disease Study 2019. *Arthritis Rheumatol* 2022;

425 **74**(7): 1172-83.

426 2. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. *Lancet* 2019; **393**(10182): 1745-59.

- 3. Bierma-Zeinstra SM, Verhagen AP. Osteoarthritis subpopulations and implications for
 clinical trial design. *Arthritis Res Ther* 2011; 13(2): 213.
- 429 4. Dell'Isola A, Allan R, Smith SL, Marreiros SS, Steultjens M. Identification of clinical
 430 phenotypes in knee osteoarthritis: a systematic review of the literature. *BMC Musculoskelet Disord*431 2016; 17(1): 425.
- 432 5. Deveza LA, Melo L, Yamato TP, Mills K, Ravi V, Hunter DJ. Knee osteoarthritis
 433 phenotypes and their relevance for outcomes: a systematic review. *Osteoarthritis Cartilage* 2017;
 434 25(12): 1926-41.
- 6. Beswick AD, Wylde V, Gooberman-Hill R, Blom A, Dieppe P. What proportion of
 patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic
 review of prospective studies in unselected patients. *BMJ Open* 2012; 2(1): e000435.
- Ramos YFM, Rice SJ, Ali SA, et al. Evolution and advancements in genomics and
 epigenomics in OA research: How far we have come. *Osteoarthritis Cartilage* 2024.
- Rai MF, Collins KH, Lang A, et al. Three decades of advancements in osteoarthritis
 research: insights from transcriptomic, proteomic, and metabolomic studies. *Osteoarthritis Cartilage* 2024; **32**(4): 385-97.
- 9. Nielsen RL, Monfeuga T, Kitchen RR, et al. Data-driven identification of predictive risk
 biomarkers for subgroups of osteoarthritis using interpretable machine learning. *Nat Commun*2024; 15(1): 2817.
- 446 10. Angelini F, Widera P, Mobasheri A, et al. Osteoarthritis endotype discovery via clustering
 447 of biochemical marker data. *Ann Rheum Dis* 2022; **81**(5): 666-75.
- 448 11. Werdyani S, Liu M, Zhang H, et al. Endotypes of primary osteoarthritis identified by
 449 plasma metabolomics analysis. *Rheumatology (Oxford)* 2021; **60**(6): 2735-44.
- 450 12. Rockel JS, Layeghifard M, Rampersaud YR, et al. Identification of a differential
- 451 metabolite-based signature in patients with late-stage knee osteoarthritis. Osteoarthr Cartil Open

452 2022; **4**(3): 100258.

- Ali SA, Espin-Garcia O, Wong AK, et al. Circulating microRNAs differentiate fastprogressing from slow-progressing and non-progressing knee osteoarthritis in the Osteoarthritis
 Initiative cohort. *Ther Adv Musculoskelet Dis* 2022; 14: 1759720X221082917.
- Li YH, Tavallaee G, Tokar T, et al. Identification of synovial fluid microRNA signature in
 knee osteoarthritis: differentiating early- and late-stage knee osteoarthritis. *Osteoarthritis Cartilage* 2016; 24(9): 1577-86.
- Ali SA, Gandhi R, Potla P, et al. Sequencing identifies a distinct signature of circulating
 microRNAs in early radiographic knee osteoarthritis. *Osteoarthritis Cartilage* 2020; 28(11): 147181.
- 462 16. Beyer C, Zampetaki A, Lin NY, et al. Signature of circulating microRNAs in osteoarthritis.
- 463 Ann Rheum Dis 2015; **74**(3): e18.
- Lin X, Tian T, Wei Z, Hakonarson H. Clustering of single-cell multi-omics data with a
 multimodal deep learning method. *Nat Commun* 2022; 13(1): 7705.
- 466 18. Kopf A, Fortuin V, Somnath VR, Claassen M. Mixture-of-Experts Variational
 467 Autoencoder for clustering and generating from similarity-based representations on single cell
 468 data. *PLoS Comput Biol* 2021; **17**(6): e1009086.
- 469 19. Rong Z, Liu Z, Song J, et al. MCluster-VAEs: An end-to-end variational deep learning470 based clustering method for subtype discovery using multi-omics data. *Comput Biol Med* 2022;
 471 150: 106085.
- Sandhu A, Espin-Garcia O, Rockel JS, et al. Association of synovial fluid and urinary
 C2C-HUSA levels with surgical outcomes post-total knee arthroplasty. *Osteoarthritis Cartilage*2024; 32(1): 98-107.
- 475 21. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of
 476 WOMAC: a health status instrument for measuring clinically important patient relevant outcomes
 477 to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. *J Rheumatol* 1988;
 478 15(12): 1833-40.
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*1983; 67(6): 361-70.
- 481 23. Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire
- to identify neuropathic components in patients with back pain. *Curr Med Res Opin* 2006; **22**(10):
- 483 1911-20.

- 484 24. Potla P, Ali SA, Kapoor M. A bioinformatics approach to microRNA-sequencing analysis.
- 485 *Osteoarthr Cartil Open* 2021; **3**(1): 100131.
- 486 25. van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ. Centering,
- 487 scaling, and transformations: improving the biological information content of metabolomics data.
- 488 *BMC Genomics* 2006; 7: 142.
- 489 26. Hauschild AC, Pastrello C, Ekaputeri GKA, et al. MirDIP 5.2: tissue context annotation
 490 and novel microRNA curation. *Nucleic Acids Res* 2023; **51**(D1): D217-D25.
- 491 27. Pastrello C, Kotlyar M, Abovsky M, Lu R, Jurisica I. PathDIP 5: improving coverage and
- 492 making enrichment analysis more biologically meaningful. Nucleic Acids Res 2024; 52(D1):
- 493 D663-D71.
- 494 28. Brown KR, Otasek D, Ali M, et al. NAViGaTOR: Network Analysis, Visualization and
 495 Graphing Toronto. *Bioinformatics* 2009; 25(24): 3327-9.
- 496 29. Fernandez-de-Las-Penas C, Florencio LL, de-la-Llave-Rincon AI, et al. Prognostic Factors
- for Postoperative Chronic Pain after Knee or Hip Replacement in Patients with Knee or Hip
 Osteoarthritis: An Umbrella Review. *J Clin Med* 2023; **12**(20).
- 30. Badgeley MA, Zech JR, Oakden-Rayner L, et al. Deep learning predicts hip fracture using
 confounding patient and healthcare variables. *NPJ Digit Med* 2019; **2**: 31.



503

504

504



505

506

Figure 1: Overall framework for Deep Learning-based Multimodal Clustering. Deeplearning framework for multimodal integration and clustering using Variational Autoencoder (VAE) modeling. Four individual decoders in the proposed VAE accurately identify the latent distribution within each domain (M1-M4) capturing the complex non-linear associations within the multimodal data. K-means approach is used for identifying three clusters from the obtained latent distribution. 'N' represents the no. of patients and 'nMx' represents the number of features in each data domain.

514



519 Figure 2. Integrated analysis of patient clustering and miRNA and metabolite feature 520 signatures. (a) Three-dimensional illustration (latent dimension 1-3) of the three clusters obtained 521 using a Variational Autoencoder-based deep learning framework. Cluster 1 (red) comprises 146 522 patients, Cluster 2 (green) consists of 138 patients, and Cluster 3 (blue) includes 130 patients. (b) 523 Molecular signature profiles for clusters 1, 2, and 3 respectively (left to right) derived through the 524 intersection of the most significant variables (p < 0.05) identified from both standardized mean differences analysis and differential expression analysis within the plasma metabolites and 525 526 miRNA domains, differentiating each cluster.

527

Table 1. Summary statistics of clinical variables within each cluster identified from variational autoencoder machine-learning modeling and K-means clustering. Frequency (percentage) are provided for categorical variables while median (Quartile 1, Quartile 3) values are presented for continuous variables according to patients within each cluster. p value is computed using wilcoxon rank sum test for continuous variables and chi-square or fisher's test as appropriate for categorical variables.

	Cluster 1 (n=146)	Cluster 2 (n=138)	Cluster 3 (n=130)	p-value between clusters
Sex				0.9
Female [N, (%)]	84 (58)	76 (55)	72 (55)	
Male [N, (%)]	62 (42)	62 (45)	58 (45)	
Age				0.37
Mean (sd)	66.2 (8.2)	65.4 (8.0)	65.5 (8.9)	
Median (Q1,Q3)	67 (62, 71)	65.0 (60.0, 70.8)	66 (60, 72)	
BMI				0.55
Mean (sd)	30.7 (6.1)	31.9 (7.7)	31.4 (7.3)	
Median (Q1,Q3)	29.2 (26.4, 33.8)	30.0 (26.5, 35.7)	31.1 (25.3, 34.7)	
HADS anxiety				0.72
normal [N, (%)]	103 (72)	98 (73)	100 (79)	
borderline [N, (%)]	21 (15)	20 (15)	13 (10)	
case [N, (%)]	19 (13)	17 (13)	14 (11)	
Missing (N)	3	3	3	
HADS depression				0.037
normal [N, (%)]	107 (74)	105 (78)	112 (87)	
borderline [N, (%)]	23 (16)	19 (14)	6 (5)	
case [N, (%)]	15 (10)	11 (8)	11 (9)	
Missing (N)	1	3	1	
painDETECT				0.011
neuropathic [N, (%)]	30 (21)	14 (10)	11 (8)	
nociceptive [N, (%)]	86 (59)	82 (59)	87 (67)	
unclear [N, (%)]	27 (18)	31 (22)	23 (18)	
Missing [N, (%)]	3 (2)	11 (8)	9 (7)	
WOMAC pain baseline				0.98
Mean (sd)	10.2 (3.5)	10.0 (3.2)	10.0 (3.7)	
Median (Q1,Q3)	10 (8, 12)	10 (8, 12)	10.0 (8.0, 12.4)	
WOMAC pain 1yr				0.34
Mean (sd)	3.7 (4.0)	3.7 (3.6)	3.2 (3.6)	
Median (Q1,Q3)	3.0 (1.0, 5.8)	3 (1, 6)	2.0 (0.2, 5.0)	
WOMAC pain change (1 yr - baseline)				0.55
Mean (sd)	-6.5 (4.1)	-6.3 (3.9)	-6.8 (4.1)	
Median (Q1,Q3)	-7 (-9, -4)	-6.0 (-9.0, -3.2)	-7.0 (-9.8, -4.0)	
WOMAC pain change categorical				0.48
≤33.3% [N, (%)]	27 (18)	33 (24)	22 (17)	
>33.3% [N, (%)]	119 (82)	105 (76)	108 (83)	
WOMAC function baseline				0.74
Mean (sd)	34.7 (11.9)	34.9 (11.4)	33.8 (12.3)	
Median (Q1,Q3)	36 (26, 41)	35.0 (26.2, 43.0)	34 (26, 41)	
Missing (N)	1	0	1	
WOMAC function 1 yr				0.24
Mean (sd)	14.8 (13.7)	14.7 (12.9)	12.8 (13.0)	
Median (Q1,Q3)	12.0 (4.2, 21.0)	11.5 (4.0, 20.8)	9.0 (2.2, 19.0)	
WOMAC function change (1 year-				0.76
baseline)				
Mean (sd)	-20.3 (13.4)	-20.0 (13.8)	-20.2 (13.3)	
Median (Q1,Q3)	-20 (-30, -11)	-18.4 (-31.0, -10.0)	-19.0 (-28.8, -11.0)	
WOMAC function change categorical				0.24
≤33.3% [N, (%)]	33 (23)	32 (23)	24 (19)	
>33.3% [N, (%)]	112 (77)	106 (77)	105 (81)	
Missing (N)	1	0		

BMI, body mass index; HADS, hospital anxiety and depression scale; Q, quartile; sd, standard deviation.



531 532

533 Figure 3. Cluster endotype signatures are associated with different physiological pathways.

(a) Network depicting unique enriched pathways from miRNA-gene targets and annotated
 pathways from metabolites associated with individual cluster endotype signatures. Labels show
 pathways with lowest q-value or highest number of annotated genes. (b) Radar plots of pathway
 categorizations from enriched pathways from miRNA-gene targets and annotated pathways from
 metabolites indicating categories most associated to individual clusters endotypes.





542 Figure 4: Machine Learning modeling for classifying response to 1 year pain and function 543 within each cluster (a) Comprehensive two-step machine learning (ML) framework wherein, 544 initially, unimodal ML models extract features from each domain, including metabolites, miRNA 545 from plasma, synovial fluid, urine, and clinical data. A second-level multimodal machine learning classifier integrates these features to efficiently classify response vs. non-response at 1 year. (b) 546 547 Receiver Operating Characteristic (ROC) plots illustrating the Area Under the Curve (AUC) for 548 individual domains, alongside the integrated AUC (in red) combining all five domains to classify 549 WOMAC pain response. (c) Receiver Operating Characteristic (ROC) plots illustrating the Area 550 Under the Curve (AUC) for individual domains, alongside the integrated AUC (in red) combining 551 all five domains to classify WOMAC function response. Notably, the integrated AUC outperforms 552 individual AUCs in Cluster 1, Cluster 2, and Cluster 3.